Promising results of the first phase led to the decision of further funding by the German Research Foundation (DFG). Together with Prof. Yardena Samuels from the Weizmann Institute of Science, we investigate intratumoral heterogeneity in melanoma and select promising neoantigen candidates suitable for vaccine studies.

The collaboration entitled “Fostering antigen spread and dissecting tumor evolution in response to neoantigen-specific cancer vaccination” started in May 2021. At TRON, Dr. Mustafa Diken is leading the project. He and his team are looking forward to the upcoming years of close scientific exchange.

Find out more about Prof. Samuel’s lab here Home | Samuels Lab